Arbutus Biopharma Corp (ABUS) Debt Components
- 2026-06-30: Long-term DebtUSD $0.00; Line of Credit Facility, Maximum Borrowing CapacityCAD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2026-03-31: Long-term DebtUSD $0.00; Line of Credit Facility, Maximum Borrowing CapacityCAD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2025-12-31: Long-term DebtUSD $0.00; Line of Credit Facility, Maximum Borrowing CapacityCAD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2025-09-30: Long-term DebtUSD $0.00; Line of Credit Facility, Maximum Borrowing CapacityCAD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
Arbutus Biopharma Corp Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Line of Credit Facility, Maximum Borrowing Capacity CAD | Line of Credit Facility, Maximum Borrowing Capacity USD | Debt Instrument, Interest Rate, Stated Percentage pure |
|---|---|---|---|---|
| 2026-06-30 | $0.00 | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $3.00M | (m) |
| 2012-12-21 | (m) | (m) | (m) | 8.00% |
| 2011-12-31 | (m) | 3.05M | $3.00M | (m) |
| 2011-12-21 | (m) | 3.05M | $3.00M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |